About
Antibody Engineering
Areas of Focus
Categories
Biologics & BiopharmaceuticalAntibody
Clinical Trials (7)
View allTotal Trials
7
As Lead Sponsor
5
As Collaborator
2
Total Enrollment
334
By Phase
PHASE2: 5PHASE1: 2
By Status
TERMINATED: 4COMPLETED: 3
Clinical Trials Pipeline7 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
Today
Hover over trial bars to see details
Recent Trials
NCT04059198Lead Sponsor
Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic Treatment Naive Subjects Infected With Hepatitis B Virus
PHASE2Terminated
5 participants
Started: Oct 10, 2019 · Completed: Apr 2, 2020
NCT04023721Lead Sponsor
Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic, Hepatitis B e Antigen-negative Subjects Infected With HBV Virus and Receiving or Stopping Treatment With a NUC Inhibitor
PHASE2Terminated
64 participants
Started: Jun 18, 2019 · Completed: Jul 16, 2020
NCT03932513Lead Sponsor
Evaluating the Effects of Inarigivir on Immune Response and Viral Markers in Chronic Hepatitis B Patients
PHASE2Terminated
8 participants
Started: Apr 11, 2019 · Completed: Dec 21, 2019
NCT03493698Lead Sponsor
A Fixed-Sequence, Drug-Drug Interaction Study Between Multiple Oral Doses of Inarigivir Soproxil and a Single Oral Dose of Midazolam in Healthy Subjects
PHASE1Completed
17 participants
Started: May 7, 2018 · Completed: Aug 27, 2018
NCT03434353Collaborator
Study to Evaluate the Safety and Antiviral Activity of Inarigivir Soproxil (Formerly: GS-9992) Plus Tenofovir Alafenamide (TAF) for 12 Weeks in Adults With Chronic Hepatitis B (CHB)
PHASE2Terminated
123 participants
Started: Feb 28, 2018 · Completed: Jan 26, 2021
Locations (1)
Headquarters
Cambridge, UK
Map
Loading map...